NICE issues final guidance on NHS use of Bayer’s Vitrakvi
Evidence from trials suggests that tumours with NTRK gene fusions shrink in response to larotrectinib
Read More
Tag: Larotrectinib
NICE backs NHS use of Bayer’s Vitrakvi via the CDF
The drug was initially considered too expensive but its cost to the NHS has been lowered
Read More
EU nod for Bayer’s Vitrakvi
European regulators have cleared Bayer’s Vitrakvi (larotrectinib) as a treatment for solid tumours displaying an NTRK gene fusion.
Read More
US approves first ever TRK inhibitor
Bayer and Loxo Oncology’s Vitrakvi has become the first ever TRK inhibitor to be approved in the US, having been cleared to treat advanced solid tumours harbouring an NTRK gene fusion.
Read More
Bayer files marketing application for larotrectinib
Bayer has filed a marketing application in Europe seeking approval for larotrectinib as treatment for TRK fusion cancer.
Read More
Bayer/Loxo’s larotrectinib gets speedy review in the US
Bayer/Loxo Oncology’s larotrectinib has been granted a priority review by the US Food and Drug Administration, which will consider its use to treat metastatic solid tumours carrying a certain genetic mutation.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
